Company: IMRX
Filing Date: 2025-05-05
Form Type: 10-Q
Source: 0001790340-25-000061
Chunk: 321

Company: Immuneering Corp
Filing Date: 2025-05-05
Form: 10-Q
Item: Part I, Item 1
Chunk 321
---
Item 1. Financial Statements

IMMUNEERING CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

March 31, 2025December 31, 2024AssetsCurrent assets:Cash and cash equivalents$35,865,696 $36,144,720 Prepaids and other current assets2,340,459 3,442,849 Total current assets38,206,155 39,587,569 Property and equipment, net1,046,549 1,122,865 Goodwill6,690,431 6,690,431 Intangible asset, net343,097 350,413 Right-of-use assets, net3,584,170 3,667,352 Other assets810,895 1,295,783 Total assets$50,681,297 $52,714,413 Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable$1,310,565 $1,958,536 Accrued expenses3,388,562 4,973,129 Other liabilities56,531 233,665 Lease liabilities352,521 338,438 Total current liabilities5,108,179 7,503,768 Long-term liabilities:Lease liabilities, net of current portion3,730,198 3,824,419 Total liabilities8,838,377 11,328,187 Commitments and contingencies (Note 10)Stockholders’ equity:Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2025 and December 31, 2024; 0 shares issued or outstanding at March 31, 2025 and December 31, 2024— — Class A common stock, $0.001 par value, 200,000,000 shares authorized at March 31, 2025 and December 31, 2024; 35,985,702 and 31,050,448 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively35,985 31,050 Class B common stock, $0.001 par value, 20,000,000 shares authorized at March 31, 2025 and December 31, 2024; 0 shares issued and outstanding at March 31, 2025 and